New Assay Analysis Software Demonstrates Scalability and

Flexibility

CARLSBAD, Calif.–(EMWNews)–While Brendan Technologies, Inc. (OTCBB: BDTE), an innovative analytical

software company, is completing the development of its powerful new

assay analysis software, STATLIA® Quantum, one

of the world’s top ten pharmaceutical

companies has already made an advance purchase of the system for one of

its worldwide locations. Neither the terms of the agreement nor the

company’s name was disclosed.

Brendan Technologies also has already inked a license agreement for

STATLIA Quantum with Invitrogen (NASDAQ:IVGN) to facilitate the analysis

of protein samples.

STATLIA Quantum offers “quantum leap”

advancement in assay analysis software due to its scalability,

flexibility, and industry-leading computational analysis tools. Written

in an advanced architectural design on a .NET framework, the new

software can be centrally administered throughout an organization by the

IT department. It has the flexibility to analyze multiple technologies

and applications in the laboratory, along with offering a number of

unique analysis tools made possible by its advanced and proprietary

computational capabilities.

“This purchase adds to the confirmation that

STATLIA Quantum is well positioned in the biopharmaceutical industry to

address currently unmet critical needs for assay analysis,”

said John Dunn, PhD, Chief Executive Officer of Brendan Technologies. “The

fact that major industry players are willing to make pre-release

purchases of STATLIA Quantum underscores the need for the unique and

advanced assay analysis capabilities that this software brings to the

drug development process.”

One of the industry’s leading experts in the

field of immunoassay and bioassay testing, Dr. Dunn serves as an IBC

Life Sciences instructor teaching comprehensive training courses on the

subject of “Analyzing Biological Assays”

to the biopharmaceutical industry, and has authored several key papers

on the subject. He has been invited by the United States Pharmacopeia

(USP) regulatory agency to make a presentation at its annual USP

Bioassay Workshop held August 14 on three methods used for drug potency

testing. Brendan has incorporated all three methods under discussion in

its new STATLIA Quantum software.

About Brendan Technologies, Inc.

Brendan Technologies, a developer and marketer of innovative analytical

software, is actively providing software solutions to improve the

accuracy, quality control, workflow, and regulatory compliance of

immunoassay and bioassay testing in laboratories in the

biopharmaceutical, clinical, research, veterinarian and agricultural

industries. The Company’s customers, many of

whom are Fortune 1000 organizations, represent some of the largest

corporations in their respective fields. Brendan Technologies is

continually redesigning and expanding its product lineup to better

capitalize on the growing demand of its target markets for more advanced

software.

Background on Immunoassay Testing

Immunoassays are one of the world’s largest

and fastest growing testing technologies used to diagnose diseases,

discover new chemical entities and biological products, provide vital

data in the development of drugs in FDA clinical trials, and assist in

quality control of drug manufacturing and drug screening. It is also one

of the largest technologies used in environmental testing. Currently,

$50 billion is spent globally on immunoassay testing, with approximately

$1 billion of that being spent on immunoassay software.

Immunoassays are highly sensitive and specific chemical tests used to

detect and quantify extremely minute substances in blood, body fluid and

other biological samples, using an immunological reaction. These tests

measure the formation of antibody-antigen complexes and detect them via

an indicator reaction. Their high specificity results from the use of

antibodies and purified antigens as reagents. High sensitivity is

achieved by using an indicator system that results in amplification of

the measured product. Immunoassays may be qualitative (positive or

negative) or quantitative (amount measured).

FORWARD-LOOKING STATEMENTS: This press release contains

forward-looking statements within the meaning of Section 27A of the

Securities Act of 1933, as amended, and Section 21E of the Securities

Exchange Act of 1934, as amended (the “Exchange

Act”), and as such, may involve risks and

uncertainties. For a discussion of such risks and uncertainties that

could cause actual results to differ from those contained in the

forward-looking statements, see “Risk Factors”

in the Company’s Annual Report on Form

10-KSB, as amended, for the most recently ended fiscal year.

Forward-looking statements, which are based on certain assumptions and

describe future plans, strategies, and expectations, are generally

identifiable by the use of words such as “believe,”

“expect,” “intend,”

“anticipate,” “estimate,”

“project,” or

similar expressions. These forward-looking statements relate to, among

other things, expectations of the business environment in which the

Company operates, projections of future performance, potential future

performance, perceived opportunities in the market, and statements

regarding the Company’s mission and vision. The Company’s

actual results, performance, and achievements may differ materially from

the results, performance, and achievements expressed or implied in such

forward-looking statements.

Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89

Get Unlimited Organic Website Traffic to your Website 
TheNFG.com now offers Organic Lead Generation & Traffic Solutions